Innate Pharma (XPAR:IPH) 3-Year Revenue Growth Rate : -3.20% (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Innate Pharma 3-Year Revenue Growth Rate?

Innate Pharma's Revenue per Share for the six months ended in Dec. 2023 was €0.21.

During the past 12 months, Innate Pharma's average Revenue per Share Growth Rate was 3.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was -3.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was -17.60% per year. During the past 10 years, the average Revenue per Share Growth Rate was 14.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Innate Pharma was 221.80% per year. The lowest was -55.00% per year. And the median was -1.35% per year.

Competitive Comparison of Innate Pharma's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Innate Pharma's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innate Pharma's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innate Pharma's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Innate Pharma's 3-Year Revenue Growth Rate falls into.

Innate Pharma 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Innate Pharma (XPAR:IPH) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Innate Pharma 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Innate Pharma's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma (XPAR:IPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (XPAR:IPH) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

IPHYF:USA IPHA:USA 0EVI:UK IDDA:Germany

Address

117, Avenue de Luminy, Marseille, FRA, 13009

Website

https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.

Innate Pharma (XPAR:IPH) Headlines

No Headlines